

improving  
outcomes  
**IO**

# Immuno-oncology treatment paradigms for first-line ES-SCLC and unresectable stage III NSCLC: a case-based programme

**FRIDAY 11 DECEMBER 2020 (CHANNEL 1)  
12:35–13:35 (CET)**

All recordings will be available for on-demand viewing until Tuesday 15 December 2020

## AGENDA & FACULTY

The role of immuno-oncology combinations in ES-SCLC:  
a clinical case study

**Andrea Ardizzoni**

Treating unresectable stage III NSCLC with immuno-oncology:  
a clinical case study

**Fabrice Barlesi**

Live panel discussion and Q&A

Chaired by **Luis Paz-Ares**



**Luis Paz-Ares (Chair)**

Hospital Universitario Doce de Octubre, Madrid, Spain



**Andrea Ardizzoni**

University Hospital, Bologna, Italy



**Fabrice Barlesi**

Gustave Roussy, Villejuif, France

## AstraZeneca's commitment to sustainability



**\$15.5 million** invested in environmental efficiency projects in 2019 (NRRGG fund)



**CPD A Lists**  
One of three companies worldwide to achieve double A listing for Climate Change and Water Security for four consecutive years



**62% of our power** is sourced or generated from renewable sources



**100% of API** (Active Pharmaceutical Ingredient) discharges from AstraZeneca sites were assessed as safe



**18% reduction** in our water use since 2015



**25% of our vehicles** in Europe, North America or Japan are hybrid or electric



AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030  
Find out more about AstraZeneca's commitment to sustainability at our website